During the past decade, Ico Institut Catala D Oncologia conducted 4 clinical trials. In the 10-year time frame, 4 clinical trials started and 3 clinical trials were completed, i.e. on average, 75% percent of trials that started reached the finish line to date. In the past 5 years, 3 clinical trials started and 3 clinical trials were completed. i.e. 100% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Ico Institut Catala D Oncologia" are "Chronic Lymphocytic Leukemia" (1 trials), "Lymphoma" (1 trials), "Metastatic Urothelial Carcinoma" (1 trials), "Non Hodgkin Lymphoma" (1 trials) and "Relapsed or Refractory Multiple Myeloma" (1 trials). Many other conditions were trialed in "Ico Institut Catala D Oncologia" in a lesser frequency.

Most popular intervention types in "Ico Institut Catala D Oncologia" are "Drug" (4 trials) and "Biological" (1 trials). Other intervention types were less common.

The name of intervention was led by "Carboplatin" (1 trials), "Daratumumab SC" (1 trials), "Gemcitabine" (1 trials), "INCB001158" (1 trials) and "Parsaclisib" (1 trials). Other intervention names were less common.

The vast majority of trials in "Ico Institut Catala D Oncologia" are 4 trials for "All" genders.

Currently, there are NaN active trials in "Ico Institut Catala D Oncologia". undefined are not yet recruiting, undefined are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were undefined completed trials in Ico Institut Catala D Oncologia, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Ico Institut Catala D Oncologia, 2 "Phase 1" clinical trials were conducted, 4 "Phase 2" clinical trials and 0 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".